Evidence map›Paper›PMID 40103935›Full record

ArticleFrontiers in neurology2025

A patient-centered qualitative evaluation of meaningful change on the NSAA and PUL in Duchenne Muscular Dystrophy.

Aviva Gillman, Teofil Ciobanu, Louise Barrett, Evan W Davies, Alexander P Murphy, Alex Johnson, Jessica Mills, Phoebe Heinrich, Krystian Przydzial, Bethany Ewens and 3 more

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Parent/caregiver perspectives of meaningful improvement in functional domains for people with CDKL5 deficiency disorder: a mixed-methods study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aviva GillmanModus Outcomes, a THREAD Company, London, United Kingdom.
Teofil CiobanuF. Hoffmann-La Roche, Basel, Switzerland.
Louise BarrettModus Outcomes, a THREAD Company, London, United Kingdom.
Evan W DaviesF. Hoffmann-La Roche, Basel, Switzerland.
Alexander P MurphyRoche Products Ltd., Welwyn Garden City, United Kingdom.
Alex JohnsonDuchenne UK, London, United Kingdom.
Jessica MillsModus Outcomes, a THREAD Company, London, United Kingdom.
Phoebe HeinrichModus Outcomes, a THREAD Company, London, United Kingdom.
Krystian PrzydzialModus Outcomes, a THREAD Company, London, United Kingdom.
Bethany EwensModus Outcomes, a THREAD Company, London, United Kingdom.
Gerrit VandenbergModus Outcomes, a THREAD Company, London, United Kingdom.
Stefan CanoModus Outcomes, a THREAD Company, London, United Kingdom.
Anna MayhewJohn Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trusts, Newcastle upon Tyne, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Duchenne Muscular Dystrophy (DMD) is a rare X-linked genetic disorder caused by mutations in the dystrophin gene. The North Star Ambulatory Assessment (NSAA) and Performance of Upper Limb (PUL) are used to measure motor performance in ambulatory and non-ambulatory individuals, respectively. There is limited published qualitative evidence on what constitutes a meaningful change on either instrument. The aim of this study is to understand meaningful change in functional abilities as measured by the NSAA and PUL at different ability levels from the perspective of individuals with DMD, caregivers of individuals with DMD, and clinicians. Methods: The study utilized a non-interventional, descriptive, cross-sectional qualitative design consisting of 69 semi-structured interviews, including individuals with DMD ( Results: The results for both instruments indicated that: (i) items that are meaningful differ based on ability level; (ii) maintaining function in lower and upper limbs is the ultimate goal; (iii) meaningful change is often reported in relation to gain or loss of specific function, as opposed to number of total points on the scale; and (iv) losing one scale point corresponds to either a partial or full loss in function and activity, which has differing impacts on daily life. Conclusion: The perception of meaningful change in DMD as measured by the NSAA is influenced by ability levels and ambulatory function, with participants describing their need to maximize certain abilities, maintain function, and retain independence. For the PUL, participants underscored the importance of maintenance of their functional abilities, and highlighted key themes related to maintaining independence in ADLs, reaching, eating/drinking, and finger function for technology use across score categories.

Indexed as

Duchenne Muscular Dystrophymeaningful changepatient-reported outcomesqualitative researchrare disease

Identifiers

PMID40103935
PMCPMC11915531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.